Christina M Annunziata

Christina M Annunziata

UNVERIFIED PROFILE

Are you Christina M Annunziata?   Register this Author

Register author
Christina M Annunziata

Christina M Annunziata

Publications by authors named "Christina M Annunziata"

Are you Christina M Annunziata?   Register this Author

68Publications

1294Reads

28Profile Views

NF-κB Signaling in Ovarian Cancer.

Cancers (Basel) 2019 Aug 15;11(8). Epub 2019 Aug 15.

Women's Malignancies Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/8/1182
Publisher Site
http://dx.doi.org/10.3390/cancers11081182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721592PMC
August 2019

Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors.

J Clin Invest 2018 08 30;128(9):3794-3805. Epub 2018 Jul 30.

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute (NCI) at Frederick, Frederick, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI99169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118601PMC
August 2018

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.

Oncotarget 2018 Mar 30;9(24):17104-17116. Epub 2018 Mar 30.

Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908309PMC
March 2018

Clinical trials in gynecologic oncology: Past, present, and future.

Gynecol Oncol 2018 02 6;148(2):393-402. Epub 2017 Dec 6.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.11.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801214PMC
February 2018

Proteasome inhibitors: structure and function.

Semin Oncol 2017 Dec 12;44(6):377-380. Epub 2018 Apr 12.

National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2018.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020165PMC
December 2017

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma.

Oncotarget 2017 Oct 13;8(47):81794-81802. Epub 2017 Sep 13.

Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20864DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669848PMC
October 2017

Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

J Natl Cancer Inst 2017 09;109(9)

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059237PMC
September 2017

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).

Oncotarget 2017 Aug 3;8(31):51402-51415. Epub 2017 May 3.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.17572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584257PMC
August 2017

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

J Clin Oncol 2017 Jul 4;35(19):2193-2202. Epub 2017 May 4.

Jung-Min Lee, Cody J. Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Liang Cao, Nicole Houston, Dana-Adriana Botesteanu, Jeffers Nguyen, William D. Figg, and Elise C. Kohn, Center for Cancer Research, National Cancer Institute, Bethesda; Ashley Cimino-Mathews, Janis M. Taube, Elizabeth Thompson, Aleksandra Ogurtsova, and Haiying Xu, The Johns Hopkins Medical Institution, Baltimore; and Tony W. Ho, AstraZeneca, Gaithersburg, MD; and Maria I. Harrell and Elizabeth M. Swisher, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493052PMC
July 2017

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Cancer Chemother Pharmacol 2017 Jul 2;80(1):165-175. Epub 2017 Jun 2.

Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3346-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361113PMC
July 2017

The clinical trials crisis in gynecologic oncology.

Gynecol Oncol 2017 06 11;145(3):481-482. Epub 2017 Apr 11.

Department of Obstetrics and Gynecology, University of Wisconsin Hospital and Clinics, Madison, WI, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.04.003DOI Listing
June 2017

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Gynecol Oncol 2016 08 28;142(2):332-40. Epub 2016 May 28.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258163075
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2016.05.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961516PMC
August 2016

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.

BMC Cancer 2016 08 24;16:678. Epub 2016 Aug 24.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2675-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997769PMC
August 2016

Monocyte and interferon based therapy for the treatment of ovarian cancer.

Cytokine Growth Factor Rev 2016 06 15;29:109-15. Epub 2016 Mar 15.

Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cytogfr.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899185PMC
June 2016

Editorial: Inhibiting PARP as a Strategic Target in Cancer.

Front Oncol 2016 15;6:91. Epub 2016 Apr 15.

National Cancer Institute , Bethesda, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831976PMC
May 2016

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Clin Cancer Res 2016 Mar 7;22(5):1067-75. Epub 2015 Oct 7.

Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia. Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia. Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775365PMC
March 2016

The role of reproductive hormones in epithelial ovarian carcinogenesis.

Endocr Relat Cancer 2015 Dec 15;22(6):R339-63. Epub 2015 Sep 15.

National Cancer InstituteNational Institutes of Health, 10 Center Drive, Building 10, 12N226, Bethesda, Maryland 20892-1906, USAWomen's Malignancies BranchNational Cancer Institute, National Institutes of Health, Center for Cancer Research, Bethesda, Maryland, USADepartment of Gynecologic OncologyWalter Reed National Military Medical Center, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0550DOI Listing
December 2015

Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?

Cancer 2015 Oct 24;121(19):3380-3. Epub 2015 Aug 24.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29394DOI Listing
October 2015

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.

BMC Cancer 2015 Mar 28;15:196. Epub 2015 Mar 28.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1231-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379550PMC
March 2015

In vitro enrichment of ovarian cancer tumor-initiating cells.

J Vis Exp 2015 Feb 18(96). Epub 2015 Feb 18.

Women's Malignancies Branch, National Cancer Institute;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/52446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354662PMC
February 2015

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

J Natl Cancer Inst 2014 Jun 19;106(6):dju089. Epub 2014 May 19.

Affiliations of authors: Medical Oncology Branch, Center for Cancer Research (J-ML, JLH, CMA, AMN, LM, JAZ, MY, NG, TMS, WDF, NA, ECK), National Clinical Target Validation Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research (JJ), Center for Interventional Oncology, Radiology, and Imaging Sciences, Clinical Center and National Cancer Institute (BJW), and Division of Cancer Treatment and Diagnosis, National Cancer Institute (JD), National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049120PMC
June 2014

Novel facts about FAK: new connections to drug resistance?

J Natl Cancer Inst 2013 Oct 23;105(19):1430-1. Epub 2013 Sep 23.

Affiliations of authors: Center for Cancer Research (CMA) and Clinical Investigations Branch, Cancer Therapy Evaluation Program (ECK), National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt255DOI Listing
October 2013

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

Invest New Drugs 2013 Feb 28;31(1):77-84. Epub 2012 Feb 28.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 12 N226, Bethesda, MD 20892-1906, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-012-9801-2
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9801-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553417PMC
February 2013

IKK-ε coordinates invasion and metastasis of ovarian cancer.

Cancer Res 2012 Nov 31;72(21):5494-504. Epub 2012 Aug 31.

Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-3993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488159PMC
November 2012

Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.

Am J Ther 2012 Mar;19(2):133-44

Translational Genomics Section, Medical Oncology Branch, National Cancer Institute, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/MJT.0b013e3181ff7a9eDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448445PMC
March 2012

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Blood 2011 Feb 16;117(8):2396-404. Epub 2010 Dec 16.

Metabolism Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr., Bethesda, MD 20892-1374, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-04-278788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062408PMC
February 2011

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.

Clin Cancer Res 2010 Sep 7;16(18):4517-26. Epub 2010 Sep 7.

Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981097PMC
September 2010

CD157 in ovarian carcinoma: how does it help us?

J Natl Cancer Inst 2010 Aug 16;102(15):1104-5. Epub 2010 Jul 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq269DOI Listing
August 2010

Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.

Cancer 2010 Jul;116(13):3276-84

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1906, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946598PMC
July 2010

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Cancer Res 2010 May 27;70(10):4005-14. Epub 2010 Apr 27.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1906, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3912DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873166PMC
May 2010

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

F1000 Biol Rep 2010 Feb 11;2. Epub 2010 Feb 11.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute 10 Center Drive - Room 12N226, Bethesda, MD 20892-1906 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3410/B2-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948351PMC
February 2010

Uterine papillary serous carcinoma: a new paradigm for treatment?

Cancer 2009 Aug;115(16):3594-6

Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24425DOI Listing
August 2009

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

J Clin Oncol 2008 Aug;26(22):3709-14

Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.10.8332DOI Listing
August 2008

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Cancer 2008 Apr;112(8):1726-32

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23374DOI Listing
April 2008

BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.

Clin Cancer Res 2007 Nov;13(22 Pt 1):6585-92

Medical Oncology Branch,Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-0327DOI Listing
November 2007

Proteomics in clinical trials and practice: present uses and future promise.

Mol Cell Proteomics 2006 Oct 30;5(10):1819-29. Epub 2006 May 30.

Laboratory of Pathology, Molecular Signaling Section, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.R600008-MCP200DOI Listing
October 2006